What caused ORMP's huge EPS miss in Q4 2022?

Oramed Pharmaceuticals ORMP's Q4 2022 EPS miss can be attributed to several factors: 1. **Financial Performance**: Oramed Pharmaceuticals reported a total revenue of $681,000 for Q4 2022. This figure suggests that the company's sales did not meet the expectations that would result in a higher EPS. |code|Ticker|Name|Date|Total Revenue|Diluted EPS|market_code| |---|---|---|---|---|---|---| |ORMP|ORMP.O|Oramed|2021 Q4|-1118000||186| |ORMP|ORMP.O|Oramed|2022 Q1|666000|-0.27|186| |ORMP|ORMP.O|Oramed|2022 Q2|674000|-0.27|186| |ORMP|ORMP.O|Oramed|2022 Q3|682000|-0.18|186| 2. **Return on Capital Employed**: During Q3 2022, Oramed Pharmaceuticals posted sales of $682 thousand, with a 34.46% increase in earnings. However, this improvement was not sufficient to positively impact EPS in Q4 2022. 3. **Earnings History**: Oramed Pharmaceuticals has a history of negative earnings, with significant losses in previous quarters. This trend indicates that the company may be struggling with operational efficiency or market conditions that impact profitability. 4. **Market Conditions**: The broader market conditions, including inflation and rising interest rates, may have impacted Oramed Pharmaceuticals' financial performance. Such conditions can lead to reduced investor confidence and lower stock prices, which may affect a company's ability to generate earnings. In conclusion, ORMP's Q4 2022 EPS miss is likely a result of a combination of factors including low revenue, operational inefficiencies, and challenging market conditions.